Different types of Toxoplasma gondii vaccines were evaluated using parasitological and histopathological means to induce immunity in Swiss pregnant mice and their pups against the challenge with virulent RH strain. Immunization was performed before mating by using live cyst vaccines (LCV), LCV-IL-2 combination, irradiated cyst vaccine (ICV) and ICV-IL-2 combination. It was demonstrated that pre-immunization with the current vaccines offered significant protection of both dams and pups. The highest level of protection was noticed in mice which received LCV-IL-2, followed by ICV-IL-2, then LCV and the least protection was elicited in dams immunized with ICV alone. The results threw light on the possibility of applying such vaccines not only in mice but also in other mammalian hosts including human.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
New onset of protein-losing enteropathy in a patient with Fontan circulation after COVID-19 vaccination: dread the cure or the disease?
Cardiol Young
January 2025
Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton and Harefield Hospitals, Guy's and St Thomas's NHS Foundation Trust, Imperial College, London, UK.
We present the case of a 31-year-old female with Fontan circulation who developed signs of protein-losing enteropathy 10 days after second COVID-19 vaccination. After standard investigations for identification of potential triggers for protein-losing enteropathy, we concluded that coronavirus disease 2019 (COVID-19) booster vaccination could have been the most probable underlying trigger. Prompt investigation of new symptoms post-vaccination in high-risk patients is necessary.
View Article and Find Full Text PDFImmunogenicity of an in-silico designed multi-epitope DNA vaccine encoding ROP21 and ROP29 of Toxoplasma gondii against both acute and chronic toxoplasmosis in BALB/c mice.
Microb Pathog
January 2025
Tropical Projects, Hitchin, United Kingdom. Electronic address:
Background: Toxoplasma infections are highly prevalent worldwide and can cause serious complications in immunocompromised individuals and lead to congenital infections in neonates. Despite ongoing efforts to develop T. gondii vaccines, none have been developed.
View Article and Find Full Text PDFAssociation of Influenza Vaccination During Pregnancy with Health Outcomes in Mothers and Children: A Population-Based Cohort Study.
Clin Pharmacol Ther
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
Immunization rates of maternal influenza vaccination during pregnancy remain suboptimal, with concerns about potential harm to the mothers and their offspring. We conducted a population-based cohort study, using mother-child linked database in Korea: (a) maternal cohort between December 2019, and March 2022; (b) neonatal cohort between September 2020, and June 2021. Exposure was defined as influenza vaccination during pregnancy.
View Article and Find Full Text PDFSafety, Immunogenicity, and Efficacy of Cytomegalovirus Vaccines: A Systematic Review of Randomized Controlled Trials.
Vaccines (Basel)
January 2025
Department of Biomedical Sciences and Public Health, Section of Hygiene, Preventive Medicine and Public Health, Polytechnic University of the Marche Region, 60126 Ancona, Italy.
Cytomegalovirus (CMV) is widespread and mostly causes asymptomatic infections in immunocompetent hosts, but it may lead to severe and life-threatening diseases in immunocompromised individuals, such as transplant patients and congenitally infected children, representing a significant public health concern. Although there are no licensed CMV vaccines, the development of a CMV vaccine is considered a high priority due to its potential to reduce the burden associated with CMV-related complications, and several approaches are under investigation. The objective of this systematic review was to synthesize the evidence on various CMV vaccines currently under clinical development.
View Article and Find Full Text PDFCorrigendum to "Sustainability of measles, rubella, and congenital rubella syndrome (CRS) elimination in the United States, January 2022 - June 2024" [Vaccine 46C (2025) 126681].
Vaccine
January 2025
National Sustainability Committee for the Elimination of Measles, Rubella, and Congenital Rubella Syndrome (NSC), United States of America.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!